Full Text pdf - NCI

More documents

Recommendations

Info

Use of a conversion factor to convert BCR-ABL values in a givenlaboratory to International Scale (IS)RNARefp210ABLRelative Conc(p210/ABLratio)RNA Ref CalculatedTiterNAD Ref.TiterLab ConversionFactor (CF)Mean ConcMean ConcRNA 1a 10870.71 48609.39 0.2236RNA 1 20.55% 15.9063% CF 1 0.77385768RNA 1b 6606.61 35243.32 0.1875RNA 2a 1468.54 35115.33 0.0418RNA 2 3.76% 1.5734% CF 2 0.41802665RNA 2b 1580.55 47241.23 0.0335RNA 3a 124.68 39678.00 0.0031RNA 3 0.250% 0.1816% CF 3 0.72776072RNA 3b 84.41 45666.08 0.0018RNA 4a 13.18 32065.47 0.0004RNA 4 0.032% 0.0212% CF 4 0.6542905RNA 4b 6.03 25429.05 0.000222Lab Conversion Factor 0.691
Goals of TKI therapy in CMLCURRENTComplete Hematologic ResponseCytogenetic ResponseComplete Cytogenetic ResponseMolecular ResponseComplete Molecular Response23Cure?
Page 1 and 2: CML MONITORING INTHE TKI ERAYasser
Page 3 and 4: 2008 WHO CLASSIFICATION OF MPNsPhil
Page 5 and 6: CML Phases5Chronic-phase CML (WHO):
Page 7 and 8: CML: Findings in PBMyelocyteBasophi
Page 9 and 10: Cytogenetic analysisKaryotype:Stand
Page 11 and 12: 11Philadelphia chromosome
Page 13 and 14: 13Iso (17)
Page 15 and 16: Fluorescent In Situ Hybridization(F
Page 17: 17Locations of the breakpoints in t
Page 20 and 21: 20RQ-PCR amplification assays:measu
Page 24 and 25: ELN 2009: Definitions of ResponseRe
Page 28 and 29: 28The BCR-ABL transcript percentpar
Page 30 and 31: RESISTANCE TO IMATINIB1ry Resistanc
Page 33 and 34: 33Suboptimal response defined by RQ
Page 35 and 36: 13th Congress of the European He
Page 37 and 38: PFS100= 2 log reductions (n=59)
Page 39 and 40: BCR-ABL kinase domain mutations1. D
Page 41 and 42: Mutations critical for 2 nd generat
Page 43 and 44: ABL KINASE DOMAIN MUTATIONS IN IMAT
Page 45 and 46: Faster and deeper molecular respons
Page 47 and 48: Predictive Value of Pretreatment BC
Page 49: 49Thank you!

Full Text pdf - NCI

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?